2023-510541-25-00
CTIS ↗
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
pharma · Chronic Lymphocytic Leukemia (CLL) · Relapsed/Refractory B-cell Malignancies · NRIX
Nurix Therapeutics
Nurix Therapeutics trial registry — 12 ClinicalTrials.gov studies with program phase, status, and indication context.
Brisbane, USA HQ
2012 Founded
350 Employees
Public company Type
NRIX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Founded
- 2012
- Employees
- 350
- Programs
- 9
- Drugs
- 4
- Patents
- 14
Nurix Therapeutics clinical trials
Registry index of 12 ClinicalTrials.gov studies linked to Nurix Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Nurix Therapeutics trial registry — 12 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Nurix Therapeutics.
-
IP — Phase 1
Clinical update -
NX-5948 — Phase 2
Clinical update -
NX-1607 — Phase 1
Clinical update -
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — Phase 1
Clinical update -
NX-5948 — Phase 3
Clinical update -
NX-5948 — Phase 2
Clinical update -
Drug Product De-TIL-0255 — Phase 1
Clinical update -
NX-2127 — Phase 1
Clinical update